Recent News

• 05.27.2025 - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
• 05.27.2025 - Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
• 05.19.2025 - Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference
• 05.19.2025 - Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference
• 05.15.2025 - Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.15.2025 - Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.12.2025 - Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF
• 05.12.2025 - Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF
• 05.08.2025 - The Citizens Life Sciences Conference 2025
• 05.08.2025 - The Citizens Life Sciences Conference 2025

Recent Filings

• 05.22.2025 - EFFECT Notice of Effectiveness
• 05.16.2025 - S-3 Registration statement under Securities Act of 1933
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - EX-99.1 EX-99.1
• 05.15.2025 - 8-K Current report
• 05.15.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.12.2025 - ARS Annual Report to Security Holders
• 05.12.2025 - DEF 14A Other definitive proxy statements
• 05.12.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material